Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.02 USD | -5.43% | -6.10% | -34.34% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.34% | 1.93B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.98% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
-3.63% | 11.7B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Chardan Research Cuts Price Target on Intellia Therapeutics to $146 From $172, Citing Q2 Results, WT1 Program Update; Buy Rating Kept